The difference between information and
expert, data-driven actionable intelligence
Welcome to the April 2015 issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the April issue!
More Evidence that Size Matters
by Jim Miller, President, PharmSource
Size has proven to be a major competitive advantage in the clinical contract research organization (CRO) industry, and if that experience is any guide, it presages how the dose CMO industry will evolve as well.
The seven largest clinical CROs, six of which are public companies today, accounted for 52% of bio/pharmaceutical industry spending on CRO services in 2014, up from… read on
How big is the market for…?
This is a handy guide to frequently requested data about the bio/pharma contract services industry.
The market for total global bio/pharmaceutical R&D spending:
|2014: $22 billion||Catalent Pharma Solutions
Presentation at JP Morgan Conference
Read more about the size of the contract services market for various segments.
Aenova Expands Injectables Capacity, Consolidates Network
Aenova has made a significant investment to expand its injectables capacity while consolidating the rest of its manufacturing network.
The company announced the completion of a €6 million ($6.6 million) investment at its injectables facility in Wolfratshausen, Germany. The project provided for the complete separation of cytotoxic and non-cytotoxic… read on
Large Molecule API Outsourcing: Lots of sizzle but where’s the steak?
The rise of biologics should be positive for the CMO sector. With the cost of a commercial large molecule manufacturing facility north of $200m, the rationale to outsource API manufacture to a third party could be viewed as compelling. Actual experience indicates that it isn’t any more compelling than for any other manufacturing activity.
PharmSource collected data on API manufacturing arrangements for therapeutic biologics as part of the research on our Trend Report CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance. Our analysis shows… read on
PharmSource President Jim Miller to Speak at INTERPHEX
Jim will be presenting at two different INTERPHEX events on Wednesday 4/22
5th Annual Pharma Contract Manufacturing & Procurement Summit
May 18 & 19 | Frankfurt, Germany
PharmSource is pleased to be a media partner for this event. Sourcing and procurement pharma delegates will meet with commercial service providers to discuss the increasing pressures to reduce costs and consistently maintain quality when outsourcing the manufacturing of APIs, Fill Finish and Packaging.
The agenda includes high-level buy-side speakers; a vendor panel debate; pre-scheduled private meetings; case studies; and more. To learn more and register: http://pcmp-summit.com/
Bio/Pharmaceutical Outsourcing Report – Special DCAT Edition
This monthly report covers deals and happenings throughout the industry. It provides expert insight into the significance of industry trends and what they mean for your business.
Find out what’s happening in commercial and clinical dose manufacturing and packaging, API small and large molecule,analytical services, business conditions, and more.
Get your copy from the PharmSource team at INTERPHEX. Or click here to download a complimentary copy.
PharmSource STRATEGIC ADVANTAGE
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact Katie Ludwick at firstname.lastname@example.org / +1-703-383-4903, ext. 107 (ET USA).